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To initiate adaptive immunity, dendritic cells (DCs)
move from parenchymal tissues to lymphoid organs
by migrating along stromal scaffolds that display the
glycoprotein podoplanin (PDPN). PDPN is expressed
by lymphatic endothelial and fibroblastic reticular
cells and promotes blood-lymph separation during
development by activating the C-type lectin re-
ceptor, CLEC-2, on platelets. Here, we describe a
role for CLEC-2 in the morphodynamic behavior
and motility of DCs. CLEC-2 deficiency in DCs
impaired their entry into lymphatics and trafficking
to and within lymph nodes, thereby reducing T cell
priming. CLEC-2 engagement of PDPN was neces-
sary for DCs to spread and migrate along stromal
surfaces and sufficient to induce membrane pro-
trusions. CLEC-2 activation triggered cell spreading
via downregulation of RhoA activity and myosin
light-chain phosphorylation and triggered F-actin-
rich protrusions via Vav signaling and Rac1 activa-
tion. Thus, activation of CLEC-2 by PDPN rearranges
the actin cytoskeleton in DCs to promote efficient
motility along stromal surfaces.
INTRODUCTION
Cell motility is crucial for trafficking of leukocytes between
tissues and for their interaction with one another and their micro-
environment. As the quintessential antigen-presenting cell,
dendritic cells (DCs) rely on migration via stromal networks to276 Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc.carry antigens long distances from parenchymal tissues to
lymph nodes (LNs), where they initiate adaptive immunity and
tolerance (Turley et al., 2010). DCs generally reside in paren-
chymal tissues as immature antigen-capturing cells. Upon
encountering pathogens or tissue damage, DCs undergo matu-
ration, which promotes the processing and presentation of major
histocompatibility complex (MHC)-peptide complexes, upregu-
lation of costimulatory molecules, and DC migration to LNs
(Randolph et al., 2005). Migratory DCs utilize the lymphatics as
highways to move to regional LNs where they have the highest
chance of interactingwith the appropriate antigen-specific T cell.
To reach LNs, tissue-resident DCsmust first crawl to and enter
afferent lymphatics, which begin as blind-ended vessels within
most parenchymal tissues and convey lymph toward the
thoracic duct (Randolph et al., 2005). Upon arrival at LNs, DCs
traverse the floor of the lymph-draining subcapsular sinus, pene-
trate the parenchyma, and then crawl along fibroblastic reticular
cells (FRCs) in the T cell-rich paracortex. To date, the only well-
established directional cues guiding tissue-derived DCs to the
LN paracortex are the chemokines CCL19 and CCL21 (Fo¨rster
et al., 1999; Schumann et al., 2010), two CCR7 ligands ex-
pressed by lymphatic endothelial cells (LECs) and FRCs (Link
et al., 2007). However, how these chemokines act as functional
gradients across such vast distances has not been adequately
explained, which raises the question of whether additional
hitherto-undiscovered migration mechanisms may also be in-
volved. Recent studies demonstrated that tissue-derived DCs
can migrate from tissues to LNs using amoeboid, integrin-
independent mechanisms (La¨mmermann et al., 2008; Frittoli
et al., 2011). However, the specific molecules that support
amoeboid movement and initiate cytoskeletal rearrangements
to cause spreading and translocation of DCs along stromal
scaffolds remain elusive.
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DC Motility via CLEC-2-PDPN InteractionsWe identified the transmembrane glycoprotein podoplanin
(PDPN, gp38, T1a) as a candidate molecule that migratory
DCs encounter en route to LNs because of its high expression
by both LECs and FRCs (Link et al., 2007; Peduto et al., 2009).
Interestingly, a steady-state function of PDPN in mature
lymphatic vessels and on FRCs has not been defined. Previous
studies have shown that PDPN is required for separation of
blood and lymphatic vessels during development, because
PDPN on lymphatics is engaged by CLEC-2 on platelets and
leads to platelet aggregation and vessel separation (Bertozzi
et al., 2010). Thus, on most backgrounds, Pdpn/ mice die
shortly after birth due to severe defects in lymphatic-vessel
formation leading to fatal edema (Bertozzi et al., 2010). PDPN
has been reported to be upregulated by dermal fibroblasts
exposed to inflammatory mediators. PDPN expression is also
increased on tumor cells, believed to promote tumor cell inva-
sion and metastatic spread, and correlated with poor prognosis
(Wicki and Christofori, 2007).
CLEC-2 (encoded by Clec1b) is a member of the dectin-1
subfamily of C-type lectin receptors (CLRs) and is the receptor
for PDPN (Watson et al., 2010). CLEC-2 expression by leuko-
cytes, including human DCs, was reported over a decade ago
(Colonna et al., 2000), but its function in these cells has remained
enigmatic. CLEC-2 was first discovered on platelets as the
receptor that induces aggregation following exposure to the
snake toxin rhodocytin. Similar to Pdpn/ mice, Clec1b/
mice are embryonic lethal due to profound defects in vascular
development (Suzuki-Inoue et al., 2010). In vitro studies have
shown that CLEC-2 plays a role in endocytosis by neutrophils
(Kerrigan et al., 2009) and may mediate engulfment of HIV type
1 (Watson et al., 2010). CLEC-2 binds to PDPN via its extracel-
lular C-type lectin-like domain, which promotes CLEC-2 multi-
merization at the plasma membrane (Watson et al., 2010).
CLEC-2 contains a hemi-immunoreceptor tyrosine-based acti-
vation motif that has a single YXXL sequence in its cytoplasmic
tail. CLEC-2 activation in platelets initiates a tyrosine-phosphor-
ylation signaling cascade mediated by Src, Syk, Vav, SLP-76,
and PLCg familymembers (Watson et al., 2010). Syk has recently
been reported to mediate phosphorylation of CLEC-2 in myeloid
cells as well (Moura˜o-Sa´ et al., 2011). Vav phosphorylation is
required for PLCg activation in platelets, and CLEC-2-induced
platelet aggregation is attenuated in the absence of Vav1 and
Vav3 (Pearce et al., 2004). Our results, described below, reveal
a role for CLEC-2 in the migratory behavior of DCs, whereby
CLEC-2-mediated rearrangement of the actin cytoskeleton is
induced by interactions with the PDPN-rich stromal scaffold.
RESULTS
DCs Interact Closely with the PDPN-Rich Lymphatic
Vessels and FRC Scaffold
Stromal cells provide three-dimensional (3D) scaffolds and
molecular cues that coordinate leukocyte migration and com-
partmentalization within lymphoid organs (Baje´noff et al.,
2007). En route to LNs, DCs migrate through lymphatics and
along the FRC network to reach the T cell zone. Previous studies
have shown that DCs make contact with LECs upon emigrating
from peripheral tissues (Baluk et al., 2007; Stoitzner et al., 2002);
however, it has not been previously demonstrated whether DCsmake direct contact with LECs or FRCs in vivo. Using multi-
photon intravital microscopy, we observed that DCs migrating
into the LN interacted closely with afferent lymphatic vessels
(Figure S1A available online), often for many minutes, before
squeezing between collagen fibers and entering the LN (Fig-
ure S1B and Movie S1). Electron microscopy further revealed
close contact between DCs and FRCs within the subcapsular
sinus (Figure S1C).
LECs and FRCs, which line the structures that DCs utilize
during migration to the T cell zone of the LN, express PDPN at
their surfaces (Farr et al., 1992). However, the precise distribu-
tion, localization, and abundance of this glycoprotein under
steady-state and inflammatory conditions has not been previ-
ously described. With the use of whole-mount staining of ear
skin, PDPNwas found to be expressed both at the tips and along
the length of lymphatic vessels, with amostly uniform distribution
(Figure 1A). Using microarray and cytometric analysis of LN
stromal cell subsets, we found that PDPN was expressed at the
messenger RNA (mRNA) and protein levels by LECs and FRCs,
but not by blood endothelial cells (Figures 1B–1D). Furthermore,
we found that the amounts of Pdpn mRNA and protein and the
localization of PDPN on lymphatics were unchanged during
inflammation (Figures 1C–1E). These results suggest that PDPN
is constitutively expressed by stromal structures in skin, lym-
phatics, and LNs under resting and inflammatory conditions.
CLEC-2 Expression by DCs
Next, we sought to determine whether the DCs express the
PDPN receptor, CLEC-2. CLEC-2 is reportedly expressed by
human and mouse platelets and various myeloid cell types,
including blood neutrophils, spleen DCs, bone-marrow-derived
DCs (BMDCs), and peritoneal macrophages (Bertozzi et al.,
2010; Colonna et al., 2000; Kerrigan et al., 2009; Moura˜o-Sa´
et al., 2011). Consistent with those reports, we found thatClec1b
mRNAwas expressed by BMDCs (Figure 2A). We also found that
Clec1b mRNA was expressed by DCs freshly isolated from skin
and LNs (Figure 2A). LN and skin DCs expressed 750-fold and
1,200-fold higher amounts ofClec1bmRNA, respectively, than
FRCs, which served as a negative control. BMDCs expressed
100-fold higher amounts of Clec1b mRNA than the negative
control. Using flow cytometry with recombinant PDPN-Fc
(rPDPN-Fc), which binds specifically to CLEC-2, we confirmed
surface expression of CLEC-2 on BMDCs (Figure 2B) and LN
DCs (Figure 2C). Thus, DCs from skin, LN, and bone-marrow
cultures express CLEC-2 at the mRNA and protein levels.
Next, we examined whether CLEC-2 surface expression
by DCs changed upon exposure to an inflammatory mediator.
We found that exposure to lipopolysaccharide (LPS) caused
CLEC-2 surface expression to increase 2-fold (Figure 2D).
However, in studieswhere wemonitored the subcellular localiza-
tion of CLEC-2 using A375 cells transfected with a CLEC-2-
green fluorescent protein (GFP) fusion protein, we found that
this molecule rapidly clustered at the plasma membrane and
then partially internalized in a dynamin-dependent manner into
vesicular structures (Figure 2E and data not shown). Thus,
CLEC-2 may be upregulated on the DC surface following expo-
sure to an inflammatory stimulus, but in a stromal cell niche
where PDPN is constitutively present, some portion of CLEC-2
may be quickly internalized following ligand engagement.Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc. 277
Figure 1. Pdpn mRNA and Protein Expression by LECs and FRCs
(A) Fluorescence microscopy of tissue whole mounts and schematics of ear skin at resting state. The scale bar represents 100 mm.
(B) Representative dot plots showing proportion of stromal cells (CD45) (left panel) and subsets of lymphoid stromal cells (FRCs, CD31PDPN+; LECs,
CD31+PDPN+; blood endothelial cells (BECs), CD31+PDPN) (right panel) in draining LNs at rest. SSC, side scatter.
(C) Graph representing the expression value (EV) of Pdpn mRNA from microarray analysis of sorted BECs, LECs, and FRCs from resting or inflamed LNs.
(D) Graph showing mean fluorescence intensity (MFI) of surface PDPN on BECs, LECs, and FRCs isolated from draining LNs 24 hr after intradermal injection of
PBS (resting) or LPS (inflamed) into ear skin. Data represent mean values and SD from four independent experiments.
(E) Fluorescence microscopy of ear skin whole mounts at 0 (resting) and 24 hr (inflamed) after intradermal LPS injection. Fluorescence images show overlays of
PDPN (red) and Lyve-1 (green) antibody staining in the tips and along the lengths of afferent lymphatic vessels. Representative black and white images from three
independent experiments show individual PDPN and Lyve-1 stains. The scale bar represents 20 mm.
Immunity
DC Motility via CLEC-2-PDPN InteractionsCLEC-2 Expression Is Required for Efficient DC
Migration to LNs
Given that PDPN is expressed along the entire migratory route
from skin to LNs and that DCs in these sites express the PDPN
receptor, CLEC-2, we tested whether the CLEC-2 pathway
contributed to theirmigration using several approaches. As a first
test, we employed fluorescein isothiocyanate (FITC) skin
painting to examine migration of skin-resident DCs to LNs in
mice lacking CLEC-2. Because Clec1b/mice exhibit neonatal
lethality, fetal liver chimeras (FLCs) were generated from wild-
type (WT) andClec1b/ embryos for evaluation of CLEC-2 func-
tion. Six weeks after reconstitution, CLEC-2 expression was
analyzed in CD11c+ and CD11c LN cells fromWT or Clec1b/
FLCs. As expected, Clec1b mRNA signal was detected in
CD11c+ cells fromWTFLCs, but notClec1b/ FLCs (Figure 3A).
Notably, the Clec1b mRNA in WT FLCs tracked with CD11c+
cells (Figure 3A), suggesting that CLEC-2 is not highly expressed
by CD11c cells in LNs. Ears of WT and Clec1b/ FLCs were
painted with FITC, and draining LNs were analyzed via flow cy-
tometry 24–72 hr later.WTmigratory DCs (FITC+CD11c+MHCIIhi)
entered the draining LNs at 24 hr; however, the percentage and
total numbers of Clec1b/ DCs were significantly reduced278 Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc.compared with WT DCs (30% and 50%, respectively; Figures
3B–3D). By 72 hr, the numbers of FITC+CD11c+MHCIIhi DCs
present in draining LNs had decreased compared with the
24 hr time point, and no differences were observed between
the conditions (Figures 3B and 3D). That no significant difference
was measured at this time point could reflect a more important
function for CLEC-2 in dermal DCs, which migrate to LNs more
rapidly than Langerhans cells. However, the dependence of
Langerhans cells, which arrive in peak numbers at 72 hr, on
CLEC-2 could not be directly evaluated in our FLCs due to their
radioresistant nature (Randolph et al., 2005). Consistent with the
decrease in Clec1b/ DC migration at 24 hr, LN cellularity was
reduced 30% at 72 hr in Clec1b/ compared with WT FLCs
(Figure 3E). This difference probably reflects an impaired adap-
tive immune response resulting from a combination of reduced
numbers of migratory DCs arriving at earlier time points and
the inability of the Clec1b/ DCs to efficiently enter the T zone
and crawl along the FRC scaffold.
As a second test, competitive in situ migration assays with WT
and Clec1b/ BMDCs were performed. WT and Clec1b/
DCs were labeled with carboxyfluorescein succinimidyl ester
(CFSE) and far-red dyes, respectively, mixed in equal numbers
Figure 2. Clec1b mRNA and Protein Expression by DCs
(A) Quantitative PCR analysis of Clec1b mRNA levels in FRCs (negative control), BMDCs, LN DCs, and skin DCs. LN and skin DCs were sorted from primary
tissues via flow cytometry. Values above bars depict the mRNA level relative to the negative control. Error bars represent mean and SD for three independent
experiments.
(B) Flow-cytometry analysis of surface CLEC-2 protein using rPDPN-Fc on WT (solid line) and Clec1b/ (dashed line) BMDCs. The gray line (filled histogram)
represents the secondary control.
(C) FACS analysis of surface CLEC-2 protein using rPDPN-Fc on freshly isolated WT LN DCs (solid line). Gray line (filled histogram), secondary control.
(D) Flow cytometry analysis of surface CLEC-2 protein using rPDPN-Fc on BMDCs treated for 12 hr with LPS (solid line) or left untreated (dashed line). The gray
line (filled histogram) represents the secondary control.
(E) Representative fluorescencemicroscopic images from three independent experiments of A375 cells transfected with CLEC-2-GFP that were either stimulated
with rhodocytin or left untreated. Top panels, overlay of F-actin (red), DAPI (blue), and CLEC-2-GFP (green). Bottom panels, CLEC-2-GFP fluorescence alone.
Scale bars represent 50 mm.
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DC Motility via CLEC-2-PDPN Interactions(2 3 105 of each), and coinjected into the same footpad. Donor
DCs arriving in the draining (popliteal) and distal LNs were
enumerated 24 hr later via flow cytometry. The numbers of
Clec1b/ DCs were significantly reduced compared with their
WT counterparts, and WT DCs migrated 3-fold more efficiently
from skin to LN (Figures 3F and 3G). Similar results were ob-
tained in experiments in which far-red-labeled WT and CFSE-
labeled Clec1b/ DCs were used, thereby ruling out any
specific effect of the fluorescent dyes on migration (data not
shown). As a third approach to confirm the role of CLEC-2 in
migration, DCs were treated with rPDPN-Fc protein prior to
injection to occupy surface CLEC-2 (see Figure 2B) and therebyoutcompete its capacity to bind endogenous PDPN on stroma.
Enumeration of migratory DCs in the draining LN revealed that
engagement of CLEC-2 with rPDPN-Fc prior to injection signifi-
cantly reduced their capacity to reach LNs (Figure S2A). Finally,
we tested the role of PDPN in DC migration from skin to LN
following local injection of short interfering RNA (siRNA). When
PDPN expression was reduced on stromal cells, DC migration
to the draining LN was reduced by 50% (Figures S2D–S2F).
Our results thus far suggested that efficient migration of DCs
requires CLEC-2 binding to PDPN on the surface of stromal cells
lining their migratory path. However, another possible explana-
tion was that Clec1b/ DCs displayed intrinsic defects inImmunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc. 279
Figure 3. DCs Utilize CLEC-2 for Efficient Migration from Skin to Draining LNs
(A) RT-PCR analysis of Clec1b mRNA in CD11c+ and CD11c cells that were magnetic-activated cell sorting (MACS)-purified from WT or Clec1b/ FLCs.
(B) Percentages of migratory (MHCIIhiFITC+) DCs among total donor (CD45.2+) DCs in draining LNs of WT and Clec1b/ FLC mice at 24 and 72 hr post-FITC
painting. Error bars represent mean and SD.
(C) Representative dot plots (gated on CD45.2+CD11c+ cells) showing MHCIIhiFITC+ DCs in WT and Clec1b/ FLCs 24 hr after FITC painting.
(D) Total numbers of migratory donor (CD45.2+CD11c+MHCIIhiFITC+) DCs in draining LNs of WT and Clec1b/ FLCs at 24 and 72 hr post-FITC painting. Error
bars represent mean and SD.
(E) Total cellularity in draining LNs collected from WT and Clec1b/ FLCs 24 and 72 hr after FITC painting. Error bars represent mean and SD.
(B, D, and E) Data represent ten mice per experimental condition from three independent experiments.
(F) FACS analysis of popliteal (draining) and axillary (distal) LN 24 hr after injection of WT (CFSE+) andClec1b/ (Far red+) DCsmixed in equal numbers (23 105 of
each) prior to injection into the footpad.
(G) Quantification of DCs arriving in popliteal LNs 24 hr after footpad injection. Data represent 15 mice per experimental condition from three independent
experiments. Error bars represent mean and SD.
(H) Histograms showing OT-1 T cell proliferation (CFSE dilution) in popliteal LN following footpad injection of OVA-peptide-loaded WT and Clec1b/ DCs.
Numbers show the percentage of divided cells among donor OT-1 T cells.
(I) Summary of data, as in (H). Data are shown as a division index. Error bars represent mean and SD.
(J) Histograms showing proliferation of OT-1 T cells upon coculture of naive, CFSE-labeled OT-1 T cells with OVA-peptide-loaded WT and Clec1b/ DCs for
48 hr. Numbers indicate the percentage of divided cells among donor OT-1 T cells. Data are representative of three independent experiments.
(K) Percentage of WT or Clec1b/ DCs that captured particulate antigen (fluorescently labeled latex beads). Error bars represent mean and SD.
Immunity
DC Motility via CLEC-2-PDPN Interactionsresponsiveness to motility cues, such as CCR7 ligands, or to
maturation stimuli. To address this possibility, we first compared
the ability of WT and Clec1b/ DCs to migrate toward a CCL21
gradient in a transwell plate. Importantly, both sets of DCs
migrated efficiently into the lower chamber in response to the
chemokine, and no significant differences were observed (Fig-
ure S2G). These data demonstrate that responsiveness to
CCR7 ligands is not impaired in Clec1b/ DCs, leading us to
conclude that the migration defect observed in Clec1b/ DCs280 Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc.was due to a CCR7-independent signaling pathway directly
downstream of CLEC-2. Second, we evaluated the ability of
WT and Clec1b/ DCs to mature in response to a proinflamma-
tory stimulus. Clec1b/ BMDCs exhibited the same phenotype
as theirWT counterparts (Figure S2H) and responded normally to
LPS by upregulating surface MHC class II and B7-2 (CD86) (Fig-
ure S2I). Thus, the impaired migratory potential of Clec1b/
DCs was not due to intrinsic defects in chemotaxis, nor was it
due to maturation.
Immunity
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observed inClec1b/DCs, we assessed the ability of migratory
DCs to stimulate naive T cells in vivo. First, mice received oval-
bumin (OVA)-peptide-loaded DCs from WT or Clec1b/ donor
mice via footpad injection, followed by intravenously adminis-
tered naive, CFSE-labeled OT-1 T cells 1 day later. OT-1 T cell
proliferation was significantly impaired in mice that received
Clec1b/ DCs compared with their WT counterparts (Figures
3H and 3I). Similar results were also observed when WT DCs
were preincubated with rPDPN-Fc prior to injection (Figures
S2B and S2C).
Second, we evaluated whether the impaired T cell responses
with Clec1b/ DCs were due to a difference in their capacity for
capturing or presenting antigen. An in vitro T cell activation assay
was used to compare the ability of WT and Clec1b/ DCs to
stimulate antigen-specific T cells. DCs were pulsed with OVA
peptide (SIINFEKL) and then cocultured with naive, CFSE-
labeled OT-I T cells. As shown in Figure 3J, OT-I T cells divided
to the same extent whether WT or Clec1b/ DCs served as
antigen-presenting cells. We then examined whether endocytic
activity might explain the different abilities of WT and Clec1b/
DCs to stimulate T cell responses in vivo and found that WT and
Clec1b/ DCs exhibited equal antigen-uptake activity (Fig-
ure 3K). Thus, Clec1b/ DCs exhibit alterations in migration
but appear to capture and present soluble antigens normally.
Collectively, these data suggest that CLEC-2 contributes to
adaptive immunity by fostering migration of antigen-bearing
DCs from tissues to LNs.
Migratory DCs Use CLEC-2 at Multiple Junctures En
Route to LNs
Having shown that migratory DCs probably encounter PDPN at
various points along their migration to LNs, we next determined
precisely where the CLEC-2-PDPN interaction played a role.
Intravital microscopy of ear skin was employed for evaluation
of whether CLEC-2 was important for DC entry into afferent
lymphatics. WT DCs rapidly associated with and were able to
enter lymphatic vessels (Figures 4A and 4C). In contrast, the
majority of Clec1b/ DCs remained in the dermis and failed to
interact with lymphatic structures (Figures 4B and 4C). Overall,
there was a 30% decrease in the amount of Clec1b/ DCs
that entered lymphatics. Furthermore, WT DCs were able to
migrate from the subcapsular sinus deep into the LN paren-
chyma, whereas Clec1b/ DCs were impaired in accessing
the paracortex and remained relatively close to the capsule, re-
sulting in a 40% reduction in the distance migrated (Figures 4D
and 4E). Finally, we evaluated the motile behavior of WT and
Clec1b/ DCs within LNs. Both WT and Clec1b/ DCs pene-
trated agarose-embedded LNs and showed motile behavior
therein (Figure 4F, Movie S2); however, fewer Clec1b/ DCs in-
filtrated the tissue (data not shown) compared with their WT
counterparts, despite equal starting numbers of WT and
Clec1b/ DCs. The directionality, displacement, and velocity
of DCs that penetrated the tissue were determined over a
120min period.WTDCs exhibited greater displacement (Figures
4G and 4H) and higher velocity (Figure 4I) compared with
Clec1b/ cells, whereas directionality was equivalent among
the two DC populations (Figure 4G). Thus, CLEC-2 expression
byDCs supports their motility atmultiple points along the journeyto LNs: from their entry of dermal lymphatics tomigration into the
LN paracortex.
CLEC-2 Activation Leads to Protrusion Formation and
Stabilization in DCs
Next, we sought to investigate the mechanism by which CLEC-2
promotes DC migration. Initially, we asked whether CLEC-2
activation might trigger DC maturation, which is known to
promote migratory potential, but no activation was observed
upon rhodocytin treatment (Figure S3). Time-lapse imaging
was then employed to examine the morphodynamic behavior
of DCs following CLEC-2 activation. DCs were cultured in 3D
collagen matrices (Hooper et al., 2006) following treatment with
either rPDPN-Fc or rhodocytin. Notably, CLEC-2 activation trig-
gered vigorous protrusive activity in WT DCs, with multiple,
highly branched protrusions extending simultaneously from the
cell body (Figure 5A, Movie S3). In contrast, Clec1b/ DCs
maintained a rounded morphology following stimulation with
either ligand (Figures 5B and 5C), indicating that protrusion
activity triggered by rPDPN-Fc or rhodocytin was CLEC-2-
dependent. Compared with untreated DCs, which maintained
amore roundedmorphology and displayed small and short-lived
pseudopods (Figures 5A–5C,Movie S3), CLEC-2 ligand-induced
protrusions extended greater distances (Figure 5D) from the cell
body, were more abundant (Figure 5E), and persisted for longer
periods of time (Figure 5F). Thus, CLEC-2 activation triggers
dramatic changes in the morphodynamic behavior of DCs,
driving the generation and stabilization of cell protrusions.
The PDPN-CLEC-2 Interaction Is Necessary and
Sufficient to Induce DC Protrusions
To further dissect the roles of CLEC-2 and PDPN in DCmigration
along stromal cell scaffolds, we engineered a 3Dmodel of the LN
stromal network by seeding primary LN FRCs into a deformable
matrix. In 3D, FRCs maintained high expression of PDPN and
remodeled the matrix to form an extensively branched, large
(50–300 mm in length) reticular structure, reminiscent of the
collagen network of the LN paracortex (Figure 6A, compare to
Figures 4D–4F). Highly motile leukocytes, such as DCs and B
cells, that were coseeded into the networks interacted with the
FRC scaffold (Figures 6A and 6B and data not shown). Time-
lapse imaging revealed that upon contact with FRCs, DCs
extended protrusions and then spread along the stromal cell
surface (Figure 6C). Where DCs reached a branch in the FRC
scaffold, protrusions were often simultaneously induced along
both potential tracks before one was retracted (Movie S4).
Notably, PDPN rapidly accumulated at sites of contact between
DCs and FRCs (Figure S4A).
Once the DCs adhered to and spread along the FRCs, they
began migrating while maintaining close contact with the
FRCs. The DCs generally migrated relatively long distances
on the FRC network: between 50 and 300 mm in any one direc-
tion over 60 min (Figure 6D, Movies S4 and S5). In contrast,
DCs not in contact with the FRC network, or cultured
alone, were relatively immotile (Figure 6Diii). Interestingly, we
found that FRCs isolated from the spleen formed similar
networks when seeded into a 3D matrix and also supported
DC migration (data not shown). We also evaluated whether
any tensile cell scaffold could induce DC migration by creatingImmunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc. 281
Figure 4. Clec1b–/– DCs Exhibit Impaired Migration In Vivo
(A) Z projection of ear dermis incubated with WT BMDCs (Ai). Lymphatic vessels are shown in green and infiltrating DCs are shown in red. The scale bar indicates
100 mm. Zoomed image showing DCs interacting with lymphatic vessel (Aii).
(B) Z projection of ear dermis incubated with Clec1b/ BMDCS (Bi). The scale bar indicates 100 mm. Zoomed image showing DCs interacting with lymphatic
vessel (Bii).
(C) Quantification of localization of WT and Clec1b/ DCs within ear sheets. Data are collated from three independent experiments. Error bars represent mean
and SD.
(D) Z projection of LN from a Ub-GFP BM chimeric mouse (WT BM >Ub-GFP host) injected withWT and Clec1b/DCs 24 hr prior to dissection and fixation (Di).
The GFP+ stroma is shown in white, WT DCs are shown in red, and Clec1b/ DCs are shown in green. The scale bar indicates 100 mm. Location of WT DCs
relative to LN capsule (dotted line) (Dii). Location of Clec1b/ DCs relative to LN capsule (dotted line) (Diii).
(E) Quantification of distance from the LN capsule. Error bars represent mean and SD.
Immunity
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DC Motility via CLEC-2-PDPN Interactionsmatrices with NIH 3T3 fibroblasts. When seeded into the NIH
3T3 network, DCs made contact with the fibroblasts but did
not migrate efficiently (Figure 6Diii), despite the fact that these
cells formed a branched network reminiscent of the FRC
scaffolds.
To determine the molecular mechanisms underlying DC
migration along FRCs, we first examined the impact of known
motility cues. Interestingly, we found that DC migration in the
in vitro 3D network occurred independently of CCR7 and its
ligands CCL19 and CCL21, as FRCs rapidly downregulated their
expression of both CCL19 and CCL21 when cultured ex vivo,
and Ccr7/ DCs migrated as efficiently as WT DCs along the
scaffold (Figures S4B–S4D). We also tested the requirement of
integrins by utilizing FRCs cultured from Icam1/ mice and
found, in agreement with published studies, that DCs did not
require engagement of this adhesion molecule for migration
along stromal networks (Figures S4E–S4G).
Having ruled out a role for CCR7 and ICAM-1 in our 3D model
of DC motility, we next directly evaluated whether CLEC-2 acti-
vation by PDPN influenced DC migration along FRC scaffolds.
To this end, we coseeded 3D matrices with different combina-
tions of DCs and FRCs lacking either CLEC-2 or PDPN and
examined DC migration on the networks. When seeded in WT
FRC matrices, Clec1b/ DCs were profoundly impaired in
migration on the FRC network compared with WT DCs (Fig-
ure 6E). In addition to impaired migration, Clec1b/ DCs also
failed to spread along the stromal cell surface, exhibiting
a distinctly rounded morphology (Figure 6E and Movie S6).
These results suggest that DCs still make contact with the FRC
network in the absence of CLEC-2 but lack the ability to spread
and crawl on this surface.
We also examined the role of PDPN in DC migration along
stromal scaffolds. Initially, we compared the motility of WT
DCs in networks formed by NIH 3T3 fibroblasts or FRCs. As
shown in Figure 6Diii, DCs did not migrate efficiently on the
NIH 3T3 fibroblasts compared with FRCs. Interestingly, NIH
3T3 cells express 80% less PDPN than cultured FRCs (Fig-
ure S4H), which led us to further examine the sufficiency of
PDPN on stroma in this interaction. To this end, we took
a gain-of-function approach by overexpressing cyan fluores-
cent protein (CFP)-PDPN in NIH 3T3 cells to ascertain whether
elevated levels of this protein would incite DC migration.
Expression of CFP-PDPN in these cells caused morphologic
changes that were consistent with previous reports linking
PDPN expression with increased invasiveness in cancer cells
(Wicki and Christofori, 2007). The CFP-PDPN+ NIH 3T3 cells
no longer formed extensive networks; however, they did exhibit
a stellate morphology when coseeded with DCs in the 3D
matrices. Interestingly, we observed enhanced interactions
between DCs and CFP-PDPN+ NIH 3T3 cells compared with
the control NIH 3T3 cells (data not shown). Furthermore,(F) Z projection of vibratome-cut GFP-ubiquitin LN slice showing the position ofW
are shown in white. The scale bar indicates 100 mm. Overlay showing tracks of W
lapse imaging (Fii). Tracks of WT (red) and Clec1b/ (green) DCs within LN slice
(G) Representative plots showing directionality of migrating WT and Clec1b/ D
were adjusted to begin at origin (0.0) and overlaid. The axes span 150 mm.
(H and I) Displacement (H) and velocity (I) of WT and Clec1b/ DCs within LN slic
four different donors, from three independent experiments. Error bars representconsistent with a requirement for CLEC-2 activation by PDPN
in this niche, we found that DC migration was severely dimin-
ished in networks formed by Pdpn/ FRCs compared with
WT FRCs (Figure 6F, Movie S7, and Figure S4I). Similarly,
WT DCs were markedly less efficient at spreading and
migrating on FRCs in which PDPN surface levels were reduced
following transfection with PDPN-targeting siRNAs compared
with control siRNA-transfected FRCs (Figure 6Fiii and Fig-
ure S4J). Thus, our findings suggest that PDPN is required
for DCs to spread and migrate efficiently along the FRC
surface.
To investigate whether CLEC-2 activation was sufficient to
induce protrusion formation, we utilized A375 cells, a human
melanoma cell line lacking CLEC-2 expression that migrates in
an amoeboid manner and exhibits a rounded morphology
(Pinner and Sahai, 2008). Control A375 cells that were seeded
into the 3D matrix maintained their rounded morphology and
did not form protrusions, whether they were in contact with
FRCs or not (Figures 6G and 6H). In contrast, A375 cells express-
ing GFP-CLEC-2 formed long protrusions only when in contact
with FRCs (Figures 6G and 6H). These results demonstrate
that overexpression of CLEC-2 by a cell type that normally lacks
it is sufficient to incite the formation of protrusions in response to
contact with PDPN-rich FRCs. Therefore, PDPN activation of
CLEC-2 is necessary and sufficient to induce dynamic protru-
sions and spreading to support migration of DCs, and potentially
any CLEC-2-expressing cell type, along PDPN-rich stromal
scaffolds.
CLEC-2 Signaling Coordinately Reduces Actomyosin
Contractility and Promotes Actin Polymerization
To elucidate the mechanism by which CLEC-2 activation
promotes cell motility, we investigated how engagement by its
ligands affects the actin cytoskeleton. CLEC-2 activation by
either rPDPN-Fc or rhodocytin led to a marked accumulation
of F-actin in the tips of newly extended protrusions, suggesting
that actin polymerization drives their formation (Figure 7A).
CLEC-2 signaling has been shown to activate a cascade of tyro-
sine-kinase signaling involving Vav (Pearce et al., 2004). Given
that Vav family members can also function as exchange factors
for Rho family GTPases (Graham et al., 2009), master regulators
of the actin cytoskeleton (Nobes and Hall, 1995), we investigated
whether the morphologic changes in DCs upon CLEC-2
activation were dependent on Vav. Whereas WT DCs exhibited
extensive protrusions upon stimulation with rhodocytin,
Vav1/Vav2/Vav3/DCsmaintained a roundedmorphology
upon CLEC-2 activation (Figure 7B). Indeed, the morphology of
the Vav1/Vav2/Vav3/ DCs was highly reminiscent of the
Clec1b/ DCs shown in Figure 5B (data not shown). These
data indicate that the cytoskeletal rearrangements and actin-
rich protrusions formed in DCs upon CLEC-2 activation areT (red) andClec1b/ (green) infiltrated DCs (Fi). GFP+ lymph node stromal cells
T (red) and Clec1b/ (green) DCs on GFP+ LN (white) over 2 hr period of time-
(Fiii).
Cs within LN slices of Ub-GFP BM chimeric mouse with GFP+ stroma. Tracks
es of Ub-GFP BM chimeric mouse. Data are collated from eight LN slices from
mean and SD.
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Figure 5. CLEC-2 Activation Induces Protrusion Formation in DCs
(A and B) Time-lapse imaging of control-, PDPN-Fc-, and rhodocytin-treated WT (A) and Clec1b/ (B) BMDCs at 0, 5, and 10 min after stimulation. Scale bars
represent 20 mm. Far-right panels, overlays of still traces from each time point.
(C–F) Morphology index (C), protrusion length (mm) (D), number of protrusions per cell (E), and protrusion persistence (min) (F) for control, rPDPN-Fc, and
rhodocytin-treated DCs from WT and Clec1b/ FLCs, as in (A) and (B). Error bars represent mean and SD.
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DC Motility via CLEC-2-PDPN Interactionsdriven by a similar cascade of tyrosine-kinase signaling, depen-
dent on Vav, as has been described in CLEC-2-induced platelet
aggregation (Watson et al., 2010).
The small G protein Rac1 is known to promote the nucleariza-
tion and polymerization of actin filaments, and its activation is
classically characterized by the spreading of lamellipodia and
induction of membrane ruffles (Nobes and Hall, 1995; Olson
and Sahai, 2009). Furthermore, rhodocytin activation of
CLEC-2 in platelets has been shown to activate Rac1 (Watson284 Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc.et al., 2010). To examine whether the cytoskeletal changes that
we observed following CLEC-2 activation by PDPN were indica-
tive of Rac1 activation, GFP-CLEC-2+ A375 cells were treated
with CLEC-2 ligands and examined in two-dimensional (2D)
culture. A375 cells expressing GFP-CLEC-2 spread rapidly
upon exposure to rhodocytin and within 5 min had spread to
cover nearly twice the surface area of neighboring untransfected
cells (Figures 7C and 7D). To directly ascertain whether CLEC-2
signaling triggers actin polymerization via Rac1, we measured
Figure 6. CLEC-2-PDPN Interaction Is
Required for DC Migration Along, but Not
Attachment to, the FRC Network
(A) Z projection of 3D FRC network with DCs. The
scale bar represents 100 mm.
(B) Representative cross-section of FRC in 3D
culture showing PDPN localization at the plasma
membrane. The scale bar represents 5 mm.
(C) Time-lapse imaging (top) and schematic
(bottom) of DC-FRC interaction at 1, 3, 6, and 9min
after contact.
(D) Transmitted-light image of WT DCs interacting
with WT FRCs in 3D network (Di). The scale bar
represents 50 mm. Diagram showing tracks of
migrating DCs over 1 hr time course (Dii). Quanti-
fication of DCmigration along primary FRCs or NIH
3T3 fibroblasts in 3D network (Diii). Each point
represents the path of one DC collated from >
three independent experiments.
(E) Transmitted-light image of Clec1b/ DCs
interacting with WT FRCs in 3D network (Ei). The
scale bar represents 50 mm. Diagram showing
tracks of migrating DCs over 1 hr time course (Eii).
Quantification of WT and Clec1b/ DC migration
along WT FRCs in 3D network (Eiii). Each point
represents the path of one DC.
(F) Transmitted-light image of WT DCs interacting
with Pdpn/ FRCs in 3D network (Fi). The scale
bar represents 50 mm. Diagram showing tracks of
migrating DCs over 1 hr time course (Fii). Quanti-
fication of WT DCs along FRCs with control siRNA,
PDPN-targeted siRNAs, or Pdpn/ FRCs in the
3D network (Fiii). Each point represents the path of
one DC.
(G) Immunofluorescence showing A375 GFP-
CLEC-2 transfectants in contact with FRCs in the
3D network. The scale bar represents 20 mm. Error
bars represent mean and SD.
(H)Quantification of cellswith protrusions, as in (G).
Immunity
DC Motility via CLEC-2-PDPN Interactionsthe levels of guanosine triphosphate (GTP)-bound Rac1 relative
to total Rac1 by protein blot following exposure of GFP-CLEC-2
A375 transfectants to either rPDPN-Fc or rhodocytin. TheseImmunity 37, 276–289experiments demonstrated that Rac1
activity was indeed increased as a result
of CLEC-2 activation (Figures 7E and
7F). Together, these results suggest that
CLEC-2 signaling, initiated by ligand
engagement, triggers actin polymeriza-
tion and protrusion formation via Rac1.
Next, we sought to understand how
CLEC-2 activation promotes spreading
along the stromal cell surface. RhoA is
known to induce myosin light chain
(MLC) phosphorylation and increase
actomyosin contractility through its inter-
action with Rho kinases (Parri and Chiar-
ugi, 2010). We wondered whether
CLEC-2 signaling may alter RhoA activity
to reduce actin contractility and thereby
permit a DC or other CLEC-2-expressing
cell to spread along the stromal cellsurface. To this end, we quantified the amounts of GTP-bound
RhoA relative to total RhoA in GFP-CLEC-2+ A375 cells that
were treated with either rPDPN-Fc or rhodocytin. CLEC-2, August 24, 2012 ª2012 Elsevier Inc. 285
Figure 7. CLEC-2 Signaling Coordinately Reduces Actomyosin Contractility and Promotes Actin Polymerization
(A) F-actin and DAPI staining of control, rhodocytin, and rPDPN-Fc-treated DCs. The scale bar represents 20 mm.
(B) Morphology index of WT and Vav1/Vav2/Vav3/ DCs. Data are collated from three individual experiments, and each data point represents the
morphology of an individual DC. Error bars represent mean and SD.
(C) Immunofluorescence of A375 cells transfected with GFP-CLEC-2 and treated with rhodocytin in 2D culture. DAPI, F-actin, and GFP fluorescence are shown.
The scale bar represents 20 mm.
(D) Quantification of area comprised by cells plated in 2D following rhodocytin stimulation relative to untransfected A375 cells. Error bars represent mean and SD.
(E) Protein blots showing levels of GFP-CLEC-2 and total and activated Rac1 and RhoA in A375 clones expressing either low or high levels of GFP-CLEC-2 or
A375 control cells following treatment with rPDPN-Fc or rhodocytin.
(F) Quantification of Rac1-GTP, as in (G) (n = 3).
(G) Quantification of RhoA-GTP, as in (G) (n = 3). Error bars represent mean and SD.
(H) Immunofluorescence of FRCs and DCs in 3D network showing DAPI, CD11c, and pMLC (S19) staining. The scale bar represents 20 mm.
(I) Quantification of pMLC fluorescence intensity in 3D network relative to untreated DCs or DCs not in contact with FRCs. Error bars represent mean and SD.
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bound RhoA compared with untreated cells (Figures 7E and 7G),
suggesting that the downstream signaling that controls contrac-
tility of the actomyosin cytoskeleton would also be reduced as
a result of CLEC-2 activation. We directly tested whether this
signaling pathway downstream of CLEC-2 might elicit a reduc-
tion in contractility of the actin cytoskeleton in DCs. MLCII is
a key subunit of the conventional myosin motor, and phosphor-
ylation of MLC at serine 19 (S19) promotes its activity (Wyckoff
et al., 2006). The phosphorylation of MLC is highly dependent
on the activity of RhoA effector kinases, and the global levels
of phosphorylated MLC (pMLC) (S19) in a cell can be used as
a measure of the overall MLCII activity and contractility of the
actin cytoskeleton (Wyckoff et al., 2006). Thus, we examined
pMLC in DCs crawling along stromal cell scaffolds, where
CLEC-2 will be activated by engagement of PDPN. Immunofluo-
rescence analysis of 3D DC-FRC cocultures revealed that DCs in
contact with the FRC network exhibited markedly reduced levels
of pMLC compared with DCs that were not in contact with FRCs
(Figures 7H and 7I). Similar measurements were taken in DCs
cultured alone in a 3D matrix and treated with CLEC-2 ligands.
A significant reduction in the levels of pMLC (S19) in DCs was
also observed following CLEC-2 activation by either rhodocytin
or rPDPN-Fc (Figure 7I). Collectively, these findings suggest
that CLEC-2 engagement by PDPN leads to a coordinate set
of events: (1) the upregulation of Rac1 activity and stimulation
of actin polymerization to drive protrusion formation, and (2)
the downregulation of RhoA activity and a decrease in pMLC
to reduce cell contractility. Together, these coordinated events
would allow cells to spread along a stromal cell scaffold, extend
actin-rich protrusions, and migrate.
DISCUSSION
Here we describe a role for CLEC-2 signaling in DC motility. The
CLEC-2 ligand PDPN is highly expressed by LECs and FRCs
lining structures that DCs encounter during migration from
tissues to LNs. CLEC-2 is expressed by skin and LN DCs, but
surface levels of this protein appear to be tightly regulated.
Engagement of CLEC-2 by PDPN coordinately reduces actomy-
osin contractility and promotes actin polymerization in DCs,
thereby allowing them to spread along stromal cell scaffolds,
extend protrusions, and migrate. The CLEC-2-PDPN interaction
promotes DC migration to LNs at all stages of this journey: from
leaving peripheral tissues and entering lymphatic vessels, to
crossing the subcapsular sinus, and finally to migrating through
LN parenchyma to the T cell zone. T cell activation in LNs was
markedly reduced despite the fact that some Clec1b/ DCs
completed the passage from skin to LN, as measured by flow
cytometry. This could suggest a preferentially important role
for CLEC-2 in a DC subset that efficiently cross-presents anti-
gens such as the CD103+ dermal DC. Alternatively, this could
suggest that CLEC-2 deficiency not only reduces DC migration
but also prevents DCs from properly interacting with the FRC
network and T cells. Consistent with this latter possibility, we
found that Clec1b/ DCs were severely impaired in spreading
and crawling on the FRC network in 3D.
Analysis of the downstream signaling components revealed
that CLEC-2 activation in DCs, as in platelets, required theadaptor protein and exchange factor Vav and led to alterations
of actin dynamics via activation of Rac1. Our study shows that
CLEC-2 activation by PDPN induces F-actin-rich protrusions
conducive to cell migration. Additionally, we find that RhoA
activity is coordinately decreased upon CLEC-2 activation. Rac
and Rho have been shown to be antagonistic in a variety of
contexts (Ohta et al., 2006; Wildenberg et al., 2006), and this
exclusivity may act to spatially separate Rho and Rac. One
potential antagonistic mechanism is the ability of Rac to induce
the translocation of p190RhoGAP to locally downregulate Rho
activity (Wildenberg et al., 2006). An opposing mechanism is
also reported whereby Rho activity leads to the activation of Fil-
GAP for inactivation of Rac (Ohta et al., 2006).
Based on the signaling events following contact between
Clec1b+ DCs and Pdpn+ stromal cells, we propose the following
model. Initially, CLEC-2 and PDPN interact and cluster on
the respective cell membranes. CLEC-2 oligomerization then
induces tyrosine-phosphorylation events via Syk, PLCg, and
Vav. Vav promotes the activity of Rac1, which indirectly and
coordinately reduces RhoA activity. These events are spatially
restricted to domains on the DC surface that are in direct contact
with PDPN. Therefore, specifically at the contacts between DCs
and FRCs, the activity of RhoA effectors, such as ROCK (Rho-
associated protein kinase), are reduced, leading to reduced
phosphorylation of MLC (Wyckoff et al., 2006) and reduced
contractility of the actomyosin cytoskeleton. We suggest that
this mechanism can explain the ability of DCs to spread along
the underlying stromal cell scaffold. The increase in Rac1 activity
then promotes actin polymerization and the induction of protru-
sions reaching along the stromal cell. As the DC reaches
forward, CLEC-2 signaling would need to be tempered to allow
RhoA effector activity to contract the cell rear and allow the
cell body to follow the protrusion (Nobes and Hall, 1995). We
have noted that CLEC-2 oligomers are rapidly internalized
following ligand binding, which may allow temporal and spatial
restriction of CLEC-2 signaling.
The utilization of our 3D coculture system provided critical
insights into leukocyte interactions with FRCs and molecular
mechanisms promoting DC migration in this stromal niche. For
example, by using this system in which primary FRCs downregu-
late chemokine expression, we discovered that PDPN-driven
activation of CLEC-2was necessary and also sufficient to induce
bona fideDCmigration in the absence of additional motility cues,
such as CCL19 and CCL21. DC migration in this system was
confined to FRC surfaces but was not directional. DCs migrated
back and forth along FRC scaffolds, suggesting that PDPN acti-
vation of CLEC-2 would not be sufficient to guide DCs in one
particular direction. Rather, simultaneous signals from chemo-
kine gradients and fluid flow in vivo would confer directionality
on DC motility. Coordination of these different signaling pro-
cesses would thereby endow DCs with the capacity to migrate
through complex stromal niches from their sentry posts in paren-
chymal tissues to tissue-draining LNs where T cell responses
commence.
CLEC-2 activation may affect the motility of other leukocytes
that express this CLR. Neutrophils have been reported to
express CLEC-2 (Kerrigan et al., 2009), and as such, their migra-
tion to infected tissues or to tertiary lymphoid structures may
also be affected upon CLEC-2 engagement of PDPN. B cells,Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc. 287
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shown), may utilize this pathway to migrate along PDPN-rich
FRCs en route to follicles in secondary lymphoid organs. Indeed,
we found that, like DCs, B cells migrate along FRCs in the 3D
culture system (Fletcher et al., 2011) and may use CLEC-2 to
move within LNs (data not shown).
Beyond LECs and LN FRCs, PDPN is expressed by splenic
FRCs (Bekiaris et al., 2007) and stromal cells in bone marrow
and thymus (data not shown). PDPN is also upregulated in tissue
fibroblasts during inflammation, and PDPN-rich stroma is often
observed in tumors, perhaps supporting the function of tumor-
infiltrating leukocytes (Wicki and Christofori, 2007). Activation
of CLEC-2 by PDPNmay therefore be a widely applicable mech-
anism promoting leukocyte motility along stromal networks of all
PDPN-rich lymphoid organs and inflamed tissues, irrespective of
which chemokine cues are present. Thus, targeting CLEC-2 to
specifically harness leukocyte migration may have significant
therapeutic potential for treating inflammatory and autoimmune
diseases.
EXPERIMENTAL PROCEDURES
Isolation and Culture of Primary Cells
LN FRCs were isolated and expanded as previously described (Fletcher et al.,
2011). For BMDCs, bone marrow was taken from the tibias and femurs of
5-week-old C57BL/6, Ccr7/, Vav1/Vav2/Vav3/, and Clec1b/ mice
and cultured in RPMI containing 10% fetal bovine serum and 3% granulocyte
macrophage colony-stimulating factor (derived from supernatant of J558L
culture) for 5–6 days. Unstimulated BMDCs were used in functional experi-
ments unless otherwise specified. For experiments in which matured BMDCs
were used, the cultures were treated with 10 ng/ml LPS for 24 hr.
3D Culture System
DCs were seeded either alone or at a 5:1 ratio with FRCs into a collagen/
matrigel matrix (Pinner and Sahai, 2008) (1.8 mg/ml Matrigel [BD Biosciences]
and 3.2 mg/ml collagen type 1 [BD Biosciences]) on glass-bottomed cell-
culture plates (MatTek). Gels were incubated at 37C with 10% CO2 in
minimum essential medium alpha containing 10% fetal calf serum (FCS) during
imaging. For experiments involving CLEC-2 activation in 3D culture, CLEC-2
ligands (rhodocytin, 200 nM and rPDPN-Fc, 0.04 mg/ml) were added to the
gel as all components were mixed.
Quantification of Cell Morphology and Cell Migration In Vitro
Using ImageJ software, we determined the area and perimeter of cells by
manually drawing around the cell shape using phase-contrast images. Ratios
were calculated as follows: perimeter2/4parea. The elongation factor was
calculated with the ImageJ ‘‘fit ellipse’’ function. The ratio of major/minor
axis was plotted for measuring cell elongation on FRCs. ImageJ was also
used to determine the cell centroid and its translocation over time to calculate
distance migrated along. The motion analysis (Figure S4B) shows three time
points, overlaid in red, green, and blue. Static cells and the collagen matrix
are shown in white; motile cells are visualized by the separation of the red,
green, and blue channels.
Analysis of DC Movement in Tissues
DC entry to lymphatic vessels was carried out as previously described
(La¨mmermann et al., 2008). In brief, ears of C57BL/6 mice were split, and
the cartilage-free half was incubated with directly conjugated Lyve-1-488 anti-
body (eBioscience) in PBS containing 1%BSA for 1 hr on ice. The stained ears
were incubated with either WT or Clec1b/ LPS-matured BMDCs labeled
with 5 mM far-red cell-tracker dye (Invitrogen) for 2 hr at 37C with 5% CO2.
Noninfiltrating DCs were then gently washed away, and ears were fixed in
1% paraformaldehyde (PFA) for 4 hr. Ear sheets were imaged with an inverted
Zeiss 510 confocal microscope.288 Immunity 37, 276–289, August 24, 2012 ª2012 Elsevier Inc.For DC migration in LNs, LNs were dissected from Ubiquitin-GFP chimeric
mice (WT BM > Ub-GFP host) and embedded in 4% low-melting-temperature
agarose at 36C. Blocks were then cooled on ice. Vibratome sections of LNs
300 mm thick were cut and incubated with RPMI containing 10% FCS for
30 min at 37C. WT and Clec1b/ BMDCs were labeled with cell-tracking
dyes, washed with PBS, then incubated with the LN slices for 90 min at
37C. After this time, LN slices were gently washed with RPMI containing
10% FCS, laid into MatTek dishes, and imaged with an inverted Zeiss 510
confocal microscope for 2 hr at 37C with 5% CO2. Z stacks of 30 mm were
projected with ImageJ Z Project. Time-lapse sequences were analyzed with
the ImageJ manual-tracking plugin to measure cell velocity and to track
individual cells.
Statistical Analysis
Statistical tests in this paper were performed with Prism software (GraphPad).
Data sets were first subjected to an F test to establish whether data to be
compared exhibited comparable SD. Following this, the appropriate tests
were performed as indicated in each figure legend. In general, comparison
of multiple groups was performed with the use of a Kruskal-Wallis ANOVA
and, if significant, followed by Dunn’s post test between individual data sets.
Comparisons of two data sets were most commonly performed with the use
of a Mann-Whitney U test.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, seven movies, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2012.05.022.
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